Available Therapies for ALK-Rearranged NSCLC

A discussion of alectinib as a standard for patients with ALK-rearranged non–small cell lung cancer and mechanisms of resistance. WATCH VIDEO

OncLiveTV

Authors: Mark A. Socinski